All resolutions concerning central nervous system medicinal products

Cannabidiol (2) Epidyolex® GW Pharmaceuticals plc Diseases of the nervous system CNS ORPHAN Dravet syndrome 100% Indication for non-quantifiable additional benefit
Cannabidiol Epidyolex® GW Pharmaceuticals plc Diseases of the nervous system CNS ORPHAN Lennox-Gastaut syndrome 100% Indication for non-quantifiable additional benefit
Vigabatrin Kigabeq® Desitin GmbH Diseases of the nervous system CNS West syndrome 100% no additional benefit
Vigabatrin (2) Kigabeq® Desitin GmbH Diseases of the nervous system CNS Epilepsy, focal seizures, < 7 years 100% no additional benefit
Lisdexamfetamindimesilat (2) Elvanse Adult® Shire Deutschland GmbH Mental illnesses CNS Attention deficit hyperactivity disorder (ADHD) 100% no additional benefit
Fremanezumab Ajovy® Teva GmbH Diseases of the nervous system CNS Migraine 1.0% Indication for considerable additional benefit
Mexiletin Namuscla® Lupin Europe GmbH Diseases of the nervous system CNS ORPHAN Myotonia 100% Hint for non-quantifiable additional benefit
Melatonin Slenyto® InfectoPharm Arzneimittel und Consilium GmbH Diseases of the nervous system CNS Sleep disorders 100% Indication for minor additional benefit
Fingolimod (5) Gilenya® Novartis Pharma GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 57% Indication for non-quantifiable additional benefit
Erenumab Aimovig® Novartis Pharma GmbH Diseases of the nervous system CNS Migraine 0.6% Indication for considerable additional benefit
Brivaracetam (2) Briviact® UCB Pharma GmbH Diseases of the nervous system CNS Epilepsy, add-on treatment 100% no additional benefit
Extrakt aus Cannabis Sativa (2, reassessment) Sativex® Almirall Hermal GmbH Diseases of the nervous system CNS Multiple sclerosis (MS), spasticity 100% Hint for minor additional benefit
Cariprazin Reagila® Recordati Pharma GmbH Mental illnesses CNS Schizophrenia 21% Hint for minor additional benefit
Ocrelizumab Ocrevus® Roche Pharma AG Diseases of the nervous system CNS Multiple sclerosis (MS) 81% Proof of minor additional benefit
Cladribin Mavenclad® Merck Serono GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 100% no additional benefit
Perampanel (3) Fycompa® Eisai GmbH Diseases of the nervous system CNS Epilepsy 100% no additional benefit
Opicapon Ongentys® Bial-Portela & Ca, S.A. Diseases of the nervous system CNS Morbus Parkinson 100% no additional benefit
Tasimelteon Hetlioz® Vanda Pharmceutical Inc Diseases of the nervous system CNS ORPHAN Non-24-hour sleep–wake disorder 100% non-quantifiable additional benefit
Pitolisant Wakix® Bioprojet Pharma SARL Diseases of the nervous system CNS ORPHAN Narcolepsy 100% non-quantifiable additional benefit
Brivaracetam Briviact® UCB Pharma GmbH Diseases of the nervous system CNS Epilepsy, add-on treatment 100% no additional benefit
Fingolimod (4) Gilenya® Novartis Pharma GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 100% no additional benefit
Safinamid Xadago® Zambon S.p.A. Diseases of the nervous system CNS Morbus Parkinson 100% no additional benefit
Vortioxetin Brintellix® Lundbeck GmbH Mental illnesses CNS Major depression 100% no additional benefit
Fingolimod (3, reassessment) Gilenya® Novartis Pharma GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 21% Hint for considerable additional benefit
Lurasidon Latuda® Takeda Pharma GmbH Mental illnesses CNS Schizophrenia 100% no additional benefit
Nalmefen Selincro® Lundbeck GmbH Mental illnesses CNS Alcohol abuse 100% no additional benefit
Fingolimod (2) Gilenya® Novartis Pharma GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 100% no additional benefit
Perampanel (2, reassessment) Fycompa® Eisai GmbH Diseases of the nervous system CNS Epilepsy 100% no additional benefit
Dimethylfumarat Tecfidera® Biogen GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 100% no additional benefit
Retigabin (3, reassessment) Trobalt® GlaxoSmithKline GmbH & Co. KG Diseases of the nervous system CNS Epilepsy, add-on treatment 100% no additional benefit
Teriflunomid Aubagio® sanofi-aventis groupe / Genzyme GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 100% no additional benefit
Lisdexamfetamindimesilat Elvanse® Shire Deutschland GmbH Mental illnesses CNS Attention deficit hyperactivity disorder (ADHD) 100% no additional benefit
Perampanel Fycompa® Eisai GmbH Diseases of the nervous system CNS Epilepsy 100% no additional benefit
Extrakt aus Cannabis Sativa Sativex® Almirall Hermal GmbH Diseases of the nervous system CNS Multiple sclerosis (MS), spasticity 100% Indication for minor additional benefit
Fampridin Fampyra® Biogen GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 100% no additional benefit
Retigabin Trobalt® GlaxoSmithKline GmbH & Co. KG Diseases of the nervous system CNS Epilepsy, add-on treatment 100% no additional benefit
Fingolimod Gilenya® Novartis Pharma GmbH Diseases of the nervous system CNS Multiple sclerosis (MS) 20% Indication for minor additional benefit
Galcanezumab Emgality® Lilly Deutschland GmbH Diseases of the nervous system CNS Migraine 1.0% Indication for considerable additional benefit